The Medicines Co. Newsletter
-
Novartis To Acquire Regulus Therapeutics And Farabursen, An Investigational Microrna Inhibitor To Treat ADPKD, The Most Common Genetic Cause Of Renal Failure
30 Apr 2025 14:34 GMT
… Novartis
Novartis is an innovative medicines company. Every day, we work to …
-
Maker of Green Giant, Crisco, Ortega will move, but keep HQ in Parsippany
30 Apr 2025 10:13 GMT
… was previously home to the Medicines Co. a drugmaker that moved its … Parsippany location in 2009. The Medicines Co. left at the end of …
-
enGene to Participate in Upcoming Investor Conferences
29 Apr 2025 11:48 GMT
… clinical-stage, non-viral genetic medicines company, today announced that management will …
-
Ensoma to Present Preclinical Data and Manufacturing Advancements for In Vivo HSC Engineering Platform to Treat Cancer, Immune Disorders and Genetic Diseases at ASGCT 28th Annual Meeting
29 Apr 2025 11:31 GMT
Ensoma, a genomic medicines company advancing the future of medicine …
-
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
13 Jan 2025 14:00 GMT
… become a diabetes and obesity medicines company. Based on the most recent …
-
nChroma Bio to Present at the American Society of Gene & Cell Therapy (ASGCT) 2025 Annual Meeting
28 Apr 2025 22:59 GMT
nChroma Bio (“nChroma”), a genetic medicines company advancing programmable in vivo delivery …
nChroma Bio is a genetic medicines company committed to addressing the limitations …
-
Capsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE)
28 Apr 2025 21:05 GMT
… fully integrated next-generation genetic medicines company with a central nervous system …
-
Encoded Therapeutics to Present New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting
28 Apr 2025 21:05 GMT
… is a clinical-stage genetic medicines company developing potentially one-time, disease …
-
Shape Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting
28 Apr 2025 20:30 GMT
… is an AI-driven genomic medicines company focused on creating curative and …
-
Scribe Achieves Milestone for In Vivo Program in Collaboration with Prevail Therapeutics, a part of Lilly’s Gene Therapy Division, and Announces ASGCT Joint Presentation on Self-Inactivating AAV Technology for Neurological and Neuromuscular Disorders
28 Apr 2025 13:22 GMT
Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR …